导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.11% | 2160/4773 |
| 近一周 | -3.23% | 3920/5462 |
| 近一月 | -9.67% | 4814/5421 |
| 近一季 | -17.70% | 4597/5209 |
| 近半年 | -2.33% | 1861/4920 |
| 近一年 | 5.97% | 1524/4366 |
| 近两年 | 106.83% | 529/2954 |
| 近三年 | 56.71% | 482/2253 |
| 成立以来 | 176.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.33% 2237/4961 |
32.26% 994/5312 |
- - |
- - |
| 2025 | 52.68% 406/4813 |
-0.75% 2392/3635 |
2.91% 1272/4076 |
49.28% 343/4524 |
0.13% 2190/4813 |
| 2024 | 7.32% 1667/3463 |
-6.16% 2016/2808 |
-4.63% 1533/3014 |
21.89% 536/3129 |
-1.61% 1771/3463 |
| 2023 | -24.91% 1973/2656 |
-3.82% 2087/2280 |
-7.80% 1915/2385 |
-10.59% 2009/2515 |
-5.30% 1314/2655 |
| 2022 | -26.32% 1390/2207 |
-17.69% 1242/1919 |
8.53% 358/2016 |
-16.19% 1419/2113 |
-1.58% 1713/2208 |
| 2021 | 12.06% 390/1822 |
-7.56% 1064/1255 |
27.44% 62/1330 |
-5.69% 845/1466 |
0.87% 1050/1822 |
| 2020 | 79.75% 43/1250 |
11.33% 16/1028 |
34.84% 21/1067 |
2.77% 998/1164 |
16.51% 164/1184 |
| 2019 | - - |
- - |
-6.02% 493/804 |
8.91% 58/850 |
10.82% 94/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 长城创业板指数增强C VS. 长安沪深300非周期A(740101) |